11月22日,在2019CDS大会(中华医学会糖尿病学分会第二十三次全国学术会议)上,中华医学会糖尿病学分会主任委员、南京鼓楼医院内分泌科主任朱大龙教授,首次在大会举办的糖尿病治疗循证医学证据研讨会上公开报告918博天娱乐官网医药在研全球首创新药——双重机制葡萄糖激酶激活剂(GKA)Dorzagliatin在未用药2型糖尿病患者中开展的单药治疗III期注册临床研究(HMM0301)结果。
On November 21st, the 2019 CDS Meeting (the 23rd Scientific Meeting of the Chinese Diabetes Society) was held in Xiamen. The Phase III clinical study results of dorzagliatin (HMS5552), the global first dual-acting glucokinase activator, were presented in the plenary session.
Phase III Monotherapy Trial (HMM0301) of Dorzagliatin Achieves Primary Efficacy Endpoint with 24-Week Topline Results
Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of type 2 diabetes, today announced that 24-week topline data of dorzagliatin’s monotherapy trial (HMM0301) will be released on November 12, 2019, and management will present the results and answer any questions via conference call.
Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced today the completion of patient enrollment for a Phase III combination trial of HMS5552 (dorzagliatin) add on to metformin.
Hua Medicine ("Hua"or the"Company", Stock Code: 2552.HK), as a pre-revenue drug development company, today announced its interim results for the six months ended June 30, 2019 (the"Review Period").
At last week's American Diabetes Association's 79th Scientific Sessions, Hua Medicine, a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, presented data from an enzyme kinetics study differentiating dorzagliatin from other glucokinase activators, and preliminary data on unbiased machine learning clustering analysis.
Hua Medicine (HKEX: 2552), announced today our updated pipeline regarding our core technology targeting glucose homeostasis and first product, a glucokinase activator dorzagliatin (HMS5552).
Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced today dosing of the first patient in a Phase I drug-drug interaction trial of HMS5552 (dorzagliatin) in patients with insufficiently controlled T2D with metformin, DPP-4 inhibitor, or SGLT2 inhibitor, alone or in combination therapy (metformin plus DPP-4 inhibitor, or metformin plus SGLT-2 inhibitor).